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ABSTRACT Multidisciplinary team (MDT) diagnosis of interstitial lung disease (ILD) has been
proposed as a gold standard, but there are no formal recommendations for MDT process or composition
and limited knowledge regarding prevalence in routine practice.
We performed a systematic evaluation of ILD diagnostic practice across a range of healthcare settings
around the world. Electronic questionnaires were distributed across all global regions via society and
collaborators networks.
Responses from 457 unique centres across 64 countries were included in the analysis. Of the 350
(76.6%) centres holding formal meetings, the majority held face-to-face MDT meetings (80%), for a
minimum of 30 min (93%), and discussed diagnosis (96.9%) and patient management (94.9%) at the
meetings. Compared with non-academic and academic non-ILD centres, ILD academic centres reported a
higher ILD caseload, held more formal MDT meetings, and were more likely to include histopathology
and rheumatology specialists in their diagnostic team. Of the centres holding MDT meetings, 5.5%
routinely discussed all new cases at such meetings.
An MDT approach to ILD diagnosis is consistently interpreted and widely implemented across a range
of routine care settings around the world. This observation will inform future ILD diagnostic agreement
studies and diagnostic pathway recommendations.
@ERSpublications
In real-world practice, ILD diagnosis uses a multidisciplinary team approach, irrespective of
country or healthcare setting http://ow.ly/I1Di30nMNTX
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ORIGINAL ARTICLE
INTERSTITIAL LUNG DISEASE
Introduction
Interstitial lung disease (ILD) is a diverse group of diseases with markedly different prognoses and
therapeutic options; idiopathic pulmonary fibrosis (IPF) is the most common and lethal [1, 2]. The
licensed antifibrotic agents, pirfenidone and nintedanib, can slow the progression of IPF [3], but they do
not reverse the disease. Thus, their arrival increases the emphasis on earlier IPF diagnosis and its accurate
differentiation from other ILDs to optimise potential therapeutic benefits.
In 2002, the American Thoracic Society (ATS)/European Respiratory Society (ERS) joint statement on the
classification of idiopathic interstitial pneumonias [4] recommended a dynamic process of
multidisciplinary team (MDT) diagnosis involving clinicians, radiologists and pathologists for diagnosis of
ILD. This recommendation was later reiterated in updated statements in 2013 [5] and 2018 [6].
Diagnosis by an MDT has been shown to improve diagnostic confidence [7, 8] and is considered by many
the gold standard for ILD. In a global study of ILD diagnostic agreement, regular MDT meeting
attendance was associated with improved diagnostic reproducibility, bringing the diagnostic performance
of experienced non-university practitioners up to the levels achieved by IPF experts [9]. While highly
experienced physicians may discriminate between IPF and non-IPF ILD with a degree of accuracy that
rivals an MDT [9], the process of a formal MDT meeting may result in a change of diagnosis [10], and
allows for knowledge exchange and broadening of expertise.
Despite these benefits of MDT meetings, a 2017 Fleischner Society White Paper [11] suggested that MDT
meetings are not required in all cases, while 2017 French guidelines [12] suggest MDT meetings should occur
in specialised centres. The French guidelines [12] state MDT meetings should be held in the presence of
relevant specialists as well as the attending pulmonologist, while the White Paper [11], and the 2018 ATS/ERS
joint statement [6], specify that MDT meetings should include a pulmonologist, radiologist and pathologist.
The ATS/ERS joint statement called for further research into the optimisation of MDTs [6]. Little is known of
how fully these guidelines are implemented in real-world practice. Given that there is a lack of evidence
regarding the optimal structure of MDT meetings in general, it is not surprising there is variable guidance.
Currently, the lack of specific guidelines for MDT meetings creates an area for greatly needed study.
Understanding the current landscape of how MDT meetings are conducted is an important first step in
understanding the optimal structure and approach of MDT meetings in the diagnosis of ILDs. The aim of
this study was to describe characteristics of current MDT practices around the world and their role in ILD
diagnosis, across a wide range of global and healthcare resource settings. Only after we learn about the
current state of MDT meetings can we then study their impact on diagnostic accuracy and identify best
practices for guideline statements.
Materials and methods
Centre participation
Centres were invited to participate between November 10, 2016 and March 31, 2017. A pragmatic,
inclusive approach to participation was used to ensure representation from a wide range of settings.
Known collaborators in 20 countries acted as regional points of contact, providing local expertise on the
geographical distribution of diagnostic centres and distributing the electronic study questionnaire and
invitation e-mail through local consortia, networks and professional links. The questionnaire was also
distributed more broadly via three respiratory society e-mail lists (South African Thoracic Society, Pan
African Thoracic Society and Lebanese Pulmonary Society) and advertised on the Respiratory Effectiveness
Group website (http://effectivenessevaluation.org) to enable volunteer participation of eligible centres. To
ensure a broad and inclusive approach, the only eligibility criterion was that respondents had to be
personally involved in the diagnosis of ILD at their centres.
Study design
A standardised, systematic questionnaire was developed using an electronic data capture tool (Qualtrics
Research Suite; Qualtrics, Provo, UT, USA). The questionnaire drew on published questionnaires relating
to aspects of ILD diagnosis, and was further refined and tailored to the purposes of this study through
ILD physician expert consensus [13, 14]. Conditional logic was built into the questionnaire to minimise
the burden on the respondent, to support data validation and to aid in quality assurance.
The questionnaire included both contextual and outcome questions (supplementary file S1). Contextual
questions covered: participants’ clinical experience; type of centre (academic/non-academic and/or ILD
specialist centre); and ILD caseload and distribution of ILD diagnoses. Outcome questions captured details
of: diagnostic tests performed before and/or at the respondent centre; key diagnostic meeting
characteristics; percentage of new cases presented at formal ILD diagnostic meetings; and access to
licensed antifibrotic agents. No definitions were given for “academic centres” or “ILD centres” and
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therefore interpretation is as classified by the respondent. “Formal” meetings were defined as those of a
scheduled or pre-planned nature, whereas “informal” meetings were defined as spontaneous and/or
unplanned.
Analysis
Where multiple responses were received from one centre, the responses were combined into a single
response. For questions about the participant, the response from the respondent with the greatest
experience was taken, while numerical responses were presented as an average of the responses from that
centre. Text responses and ranges were combined where possible. Where this was not possible, the most
pessimistic response was taken. The economic status of a country was defined using the World Bank
Income Groups [15]. Data were analysed using R version 3.3.3 (www.r-project.org). Results are reported as
percentages, mean with standard deviation or median (interquartile range (IQR)) and group comparisons
made using the Kruskal–Wallis test, Chi-squared test or Fisher’s exact test.
Results
Between November 10, 2016 and March 31, 2017, 1633 centres were invited to take part in the study and
further centres recruited indirectly. In total, 570 responses were received. The overall response rate could
not be calculated as denominator data are not available for individuals recruited indirectly through study
collaborator networks (n=215) or who responded through the website (n=68). The response rate for those
recruited through e-mails by study collaborators was 48.4% (247 out of 510), while the response rate for
those recruited through pulmonary society e-mail lists (which will have included many non-ILD
specialists) was 5% (40 out of 805) (figure 1).
Of the 570 responses collected, seven participants did not complete the questionnaire, 17 were not directly
involved in ILD diagnosis, and 89 were identified as duplicate responses and merged with existing records
(figure 1).
Centre and respondent demographics
A total of 457 valid responses from 64 countries were included in the analysis, of which 90.8% (415) were
completed between November 2016 and January 2017. The median (IQR) time taken to complete a
questionnaire was 18.5 (11.6–31.7) min. However, as the questionnaire allowed respondents to save and
return to their response, this likely overestimates the average questionnaire duration.
The majority (n=318 (69.6%)) of respondents reported ⩾11 years experience post-specialisation and 404
(88.4%) were pulmonology specialists. Europe contributed the greatest number of centres (n=173 (37.9%))
followed by Asia-Pacific (n=120 (26.3%)), with the lowest number of centres in the Middle East (n=24
(5.3%)) and Africa (n=16 (3.5%)). Most centres were in high-income countries (n=306 (67.0%)), with only
510 potential participants e-mailed
by study collaborators
215 responses through study 
collaborator networks
247 responses (48.8%)
68 responses through REG 
website
89 duplicate responses (15.6%)
7 incomplete responses (1.2%)
17 participants not involved in ILD
  diagnosis (3.0%)
40 responses (5%)
805 potential participants e-mailed 
through pulmonary societies
570 responses collected
457 valid responses included
FIGURE 1 Flowchart of participant recruitment. REG: Respiratory Effectiveness Group; ILD: interstitial lung
disease.
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two from low-income countries (0.4%) (table 1). Nearly half the respondents reported working in ILD
academic centres (n=205 (44.9%)), 29.1% in non-ILD academic centres (n=133) and 26.0% in
non-academic centres (n=119).
Caseload, case mix and case management
Centres saw an estimated median (IQR) 16 (10–28) new ILD cases per month, of which 4 (2–7) were IPF
cases. Non-ILD academic centres and non-academic centres reported similar IPF (p=0.918) and non-IPF ILD
(p=0.252) caseloads, while ILD academic centres reported significantly higher caseloads of both IPF and
non-IPF ILD than other centre types (p<0.001) (table 1).
Overall, IPF was the most frequently reported ILD diagnosis and accounted for a mean±SD 23.4±14.5% of ILD
cases; connective tissue disease-related ILD (16.1±10.7%) and sarcoidosis (15.7±13.4%) were the next most
common diagnoses. Europe was the only global region where IPF was not the most common ILD diagnosis;
European centres reported a higher incidence of sarcoidosis than IPF (20.8% versus 20.1%, respectively).
ILD academic centres managed a lower percentage of cases than either non-ILD academic centres or
non-academic centres (table 1). The difference, however, was not significant for IPF cases (p=0.197) and
only weakly so for non-IPF cases in ILD academic centres versus non-academic centres (p=0.040). ILD
academic centres were more likely to receive patients referred from another pulmonologist than other
centre types (p<0.001) (table 1).
Diagnostic tests
All 457 centres reported use of spirometry (n=453 (99.1%)) or diffusing capacity of the lung for carbon
monoxide (DLCO) (n=432 (94.5%)) to assess most patients, either prior to or on arrival at the centre. All
centres also reported use of high-resolution computed tomography (HRCT) for most patients and 450
centres (98.5%) reported that chest radiography was performed for most patients.
DLCO was most commonly performed in ILD academic centres (p=0.020), in centres in high-income
countries (p<0.001), and in Europe and North America (p<0.001) (table 2). No significant differences
were seen in the proportion of centres conducting spirometry, HRCT or chest radiography across centre
TABLE 1 Key features of participating centres by centre type
All centres ILD academic
centres
Non-ILD academic
centres
Non-academic
centres
p-value
Centres 457 205 133 119
Region <0.001#
Africa 16 (3.5) 5 (2.4) 7 (5.3) 4 (3.4)
Asia-Pacific 120 (26.3) 41 (20.0) 52 (39.1) 27 (22.7)
Europe 173 (37.9) 91 (44.4) 32 (24.1) 50 (42.0)
Middle East 24 (5.3) 5 (2.4) 13 (9.8) 6 (5.0)
North America 63 (13.8) 42 (20.5) 9 (6.8) 12 (10.1)
South and Latin America 61 (13.3) 21 (10.2) 20 (15.0) 20 (16.8)
Country income level 0.028
High 306 (67.0) 148 (72.2) 83 (62.4) 75 (63.0)
Upper-middle 122 (26.7) 49 (23.9) 42 (31.6) 31 (26.1)
Lower-middle 27 (5.9) 6 (2.9) 8 (6.0) 13 (10.9)
Low 2 (0.4) 2 (1.0) 0 (0.0) 0 (0.0)
Estimated new cases of ILD per month n
IPF 4 (2–7 (0–50)) 5 (3–10 (0–50)) 4 (2–5 (0–35)) 3 (2–5 (0–50)) <0.001#
Non-IPF 11 (6–20 (0–100)) 16 (10–27 (1–130)) 10 (5–20 (1–101)) 10 (5–15 (0–200)) <0.001#
Estimated cases diagnosed with IPF % 23.4±14.5 22.2±12.0 23.0±13.5 25.8±18.7 0.061¶
ILD cases managed in the centre %
IPF 90 (52–100 (0–100)) 88 (50–100 (0–100)) 90 (70–100 (0–100)) 90 (45–100 (0–100)) 0.197#
Non-IPF 88 (54–100 (0–100)) 81 (50–98 (4–100)) 87 (50–100 (0–100)) 90 (75–100 (0–100)) 0.040+
Cases referred by %
Another pulmonologist 50 (30–50 (0–100)) 50 (30–67 (0–100)) 20 (0–35 (0–85)) 5 (0–25 (0–90)) <0.001#
Primary care physician 20 (10–40 (0–100)) 15 (5–30 (0–100)) 30 (15–50 (0–100)) 34 (10–60 (0–100)) <0.001#
Data are presented as n, n (%), median (interquartile range (range)) or mean±SD, unless otherwise stated. ILD: interstitial lung disease; IPF:
idiopathic pulmonary fibrosis. #: Kruskal–Wallis test, ILD academic centres compared with all other centre types; ¶: t-test, ILD academic
centres compared with non-academic centres; +: Kruskal–Wallis test, ILD academic centres compared with non-academic centres.
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TABLE 2 Diagnostic tests performed in the majority of idiopathic pulmonary fibrosis patients
Prior to arrival On
arrival
Not
performed
p-value: prior to
arrival vs on arrival
p-value: performed
at any time vs not
performed
Total Of which repeated
on arrival
Spirometry
Centre type <0.001# 1.00¶
ILD academic 156 (76.1) 137 (87.8) 47 (22.9) 2 (1.0)
Non-ILD academic 54 (40.6) 48 (88.9) 78 (58.6) 1 (0.8)
Non-academic 46 (38.7) 40 (87.0) 72 (60.5) 1 (0.8)
Country income level <0.001¶ (<0.001#)+ 0.479¶ (0.469¶)+
High 198 (64.7) 175 (88.3) 106 (34.6) 2 (0.7)
Upper-middle 53 (43.4) 45 (84.9) 67 (54.9) 2 (1.6)
Lower-middle 5 (18.5) 5 (100) 22 (81.5) 0 (0.0)
Low 0 (0.0) 0 (NA) 2 (100.0) 0 (0.0)
Region <0.001# 0.937¶
Africa 0 (0.0) 0 (NA) 16 (100.0) 0 (0.0)
Asia-Pacific 51 (42.5) 45 (88.2) 68 (56.7) 1 (0.8)
Europe 125 (72.3) 111 (88.8) 46 (26.6) 2 (1.2)
Middle East 6 (25.0) 4 (66.7) 18 (75.0) 0 (0.0)
North America 51 (81.0) 44 (86.3) 12 (19.0) 0 (0.0)
South and Latin
America
23 (37.7) 21 (91.3) 37 (60.7) 1 (1.6)
All centres 256 (56.0) 225 (87.9) 197 (43.1) 4 (0.9)
DLCO
Centre type <0.001# 0.020¶
ILD academic 76 (37.1) 70 (92.1) 124 (60.5) 5 (2.4)
Non-ILD academic 14 (10.5) 12 (85.7) 110 (82.7) 9 (6.8)
Non-academic 14 (11.8) 7 (50.0) 94 (79.0) 11 (9.2)
Country income <0.001¶ (<0.001¶)+ <0.001¶ (<0.001¶)+
High 89 (29.1) 83 (93.3) 215 (70.3) 2 (0.7)
Upper-middle 14 (11.5) 5 (35.7) 93 (76.2) 15 (12.3)
Lower-middle 1 (3.7) 1 (100.0) 19 (70.4) 7 (25.9)
Low 0 (0.0) 0 (NA) 1 (50.0) 1 (50.0)
Region <0.001¶ <0.001¶
Africa 0 (0.0) 0 (NA) 11 (68.8) 5 (31.3)
Asia-Pacific 19 (15.8) 15 (78.9) 90 (75.0) 11 (9.2)
Europe 40 (23.1) 39 (97.5) 132 (76.3) 1 (0.6)
Middle East 4 (16.7) 0 (0.0) 17 (70.8) 3 (12.5)
North America 40 (63.5) 34 (85.0) 23 (36.5) 0 (0.0)
South and Latin
America
1 (1.6) 1 (100.0) 55 (90.2) 5 (8.2)
All centres 104 (22.8) 89 (85.6) 328 (71.8) 25 (5.5)
HRCT
Centre type <0.001# NA
ILD academic 140 (68.3) 105 (75.0) 65 (31.7) 0 (0.0)
Non-ILD academic 74 (55.6) 53 (71.6) 59 (44.4) 0 (0.0)
Non-academic 50 (42.0) 37 (74.0) 69 (57.9) 0 (0.0)
Country income 0.485¶ (0.339#)+ NA
High 184 (60.1) 131 (71.2) 122 (39.9) 0 (0.0)
Upper-middle 64 (52.5) 53 (82.8) 58 (47.5) 0 (0.0)
Lower-middle 15 (55.6) 10 (66.7) 12 (44.4) 0 (0.0)
Low 1 (50.0) 1 (100.0) 1 (50.0) 0 (0.0)
Region 0.026# NA
Africa 5 (31.3) 5 (100.0) 11 (68.8) 0 (0.0)
Asia-Pacific 82 (68.3) 58 (70.7) 38 (31.7) 0 (0.0)
Europe 92 (53.2) 70 (76.1) 81 (46.8) 0 (0.0)
Middle East 12 (50.0) 10 (83.3) 12 (50.0) 0 (0.0)
North America 39 (61.9) 26 (66.7) 24 (38.1) 0 (0.0)
South and Latin
America
34 (55.7) 26 (76.5) 27 (44.3) 0 (0.0)
All centres 264 (57.8) 195 (73.9) 193 (42.2) 0 (0.0)
Continued
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types, country income groups or regions (table 2). Spirometry (56.0%), HRCT (57.8%) and chest
radiography (89.5%) were most commonly performed for the first time prior to arrival at the centre, while
DLCO was more frequently performed at the centre (71.8%) (table 2). Most centres repeated spirometry,
DLCO and HRCT tests, when these had been performed prior to arrival (87.9%, 85.6% and 73.9%,
respectively). Chest radiography was repeated on arrival by 48.2% of centres (table 2).
Surgical lung biopsy, transbronchial biopsy and bronchoalveolar lavage (BAL) were performed on arrival
at the centre in a median (IQR) of 10.0% (5.0–25.0%), 15.0% (5.0–36.0%) and 50.0% (20.0–80.0%) of
patients, respectively (figure 2). Few centres performed endoscopic lung cryobiopsy on arrival (31.1%
utilised it in at least 1% of cases). The tests performed on arrival at the centre varied by region, with
surgical lung biopsy used most frequently in the Middle East (median (IQR) 20.0% (10.0–26.3%) of
patients) and South and Latin America (20.0% (10.0–30.0%) of patients). Transbronchial biopsy was the
most commonly used biopsy technique in the Middle East (40.0% (12.5–67.8%) of patients) and BAL in
Europe (80.0% (40.0–90.0%) of patients) (figure 2). Further tests performed are presented in
supplementary file S2.
MDT meetings
Meeting formality
Of the 457 participating centres, 362 (79.2%) reported holding meetings to discuss new cases and referrals.
Of the 95 centres who reported not holding any meetings to discuss cases, 94 (98.9%) provided a free-text
description of the steps they take when they cannot confidently diagnose a case of ILD. Of these, 45
(47.9%) reported they would discuss the case with colleagues in their centre or at other centres, 35 (37.2%)
that they would consider performing a biopsy and 23 (24.5%) that they may refer the case to another
centre.
Physicians in ILD academic centres were more likely to attend meetings (198 out of 205 (96.6%)) than
physicians in non-ILD academic centres (93 out of 133 (69.9%)) or non-academic centres (71 out of 119
(59.6%); p<0.001). Physicians in ILD academic centres also reported attending a higher proportion of
formal meetings (median (IQR) 80.5% (54.8–93.0%)) than physicians in either non-ILD academic centres
(60.0% (31.0–81.0%)) or non-academic centres (60.0% (27.5–90.0%); p<0.001). Of the 362 physicians
attending meetings, 12 (3.3%) reported attending no formal meetings. The median ratio of formal to
informal meeting attendance was 3:1.
TABLE 2 Continued
Prior to arrival On
arrival
Not
performed
p-value: prior to
arrival vs on arrival
p-value: performed
at any time vs not
performed
Total Of which repeated
on arrival
Chest radiography
Centre type 0.006# 0.296¶
ILD academic 191 (93.2) 95 (49.7) 9 (4.4) 5 (2.4)
Non-ILD academic 112 (84.2) 62 (55.4) 19 (14.3) 2 (1.5)
Non-academic 106 (89.1) 40 (37.7) 13 (10.9) 0 (0.0)
Country income 0.387¶ (0.258¶)+ NA
High 269 (87.9) 127 (47.2) 30 (9.8) 7 (2.3)
Upper-middle 111 (91.0) 54 (48.6) 11 (9.0) 0 (0.0)
Lower-middle 27 (100.0) 15 (55.6) 0 (0.0) 0 (0.0)
Low 2 (100.0) 1 (50.0) 0 (0.0) 0 (0.0)
Region <0.001¶ 0.656¶
Africa 16 (100.0) 11 (68.8) 0 (0.0) 0 (0.0)
Asia-Pacific 86 (71.7) 45 (52.3) 31 (25.8) 3 (2.5)
Europe 167 (96.5) 82 (49.1) 4 (2.3) 2 (1.2)
Middle East 21 (87.5) 9 (42.9) 3 (12.5) 0 (0.0)
North America 61 (96.8) 22 (36.1) 0 (0.0) 2 (3.2)
South and Latin
America
58 (95.1) 28 (48.3) 3 (4.9) 0 (0.0)
All centres 409 (89.5) 197 (48.2) 41 (9.0) 7 (1.5)
Data are presented as n (%), unless otherwise stated. ILD: interstitial lung disease; DLCO: diffusing capacity of the lung for carbon monoxide;
HRCT: high-resolution computed tomography; NA: not applicable. #: Chi-squared test; ¶: Fisher’s exact test; +: p-values in parentheses
exclude low-income countries due to low numbers.
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Case representation
Centres reported that a median (IQR) of 75% (50–90%) of new ILD cases were discussed at formal
meetings. 56 centres (15.5%) reported 100% of cases were discussed at formal meetings, while 14 centres
(3.9%) reported cases were only presented at informal meetings. There was no significant difference
between the median (IQR) percentage of new cases discussed at formal meetings in ILD academic centres
(77.5% (50.0–90.0%)) compared with non-ILD academic centres (70.0% (40.0–85.0%)) or non-academic
centres (77.0% (42.0–94.5%); p=0.072). However, there was some evidence of regional variation, with
centres in Europe reporting they discussed a median (IQR) of 80.0% (61.0–92.0%) of cases at formal
meetings compared with 64.0% (30.0–86.0%) in South and Latin America and 60.0% (45.5–88.0%) in
Africa (p=0.049). Centres in lower- to middle-income countries reported discussing a lower proportion of
new cases in formal meetings (median (IQR) 50.0% (20.0–87.0%)) than centres in upper-middle-(67.0%
(40.0–85.5%)) or high-income countries (80.0% (58.8–92.0%); p=0.006). Only one of the two centres in
low-income countries reported holding diagnostic meetings. This centre reported discussing 60% of cases
at their formal meetings.
Meeting format, regularity and team composition
In the 350 centres (76.6%) holding formal meetings, these meetings were most often solely face-to-face
(n=280 (80.0%)) and almost all (n=340 (97.1%)) had some face-to-face component. Formal meetings were
most often held once a week (n=122 (34.9%)), were 31–60 min long (n=178 (50.9%)), discussed 1–5 cases
(n=212 (60.6%)) and had a median (IQR) of 4 (3–5) disciplines in attendance. Most meetings ⩽90 min
long discussed 1–5 cases (186 out of 290 (64.1%)) compared with 43.3% (26 out of 60) of meetings
>90 min long (figure 3).
The format of meetings varied regionally and by centre type (table 3). ILD academic centres were more
likely to hold formal meetings (196 out of 205 (95.6%)) than either non-ILD academic centres (87 out of
100a)
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FIGURE 2 Box-and-whisker plots of percentage of patients receiving a) surgical lung biopsy, b) transbronchial biopsy, c) endoscopic lung
cryobiopsy or d) bronchoalveolar lavage at the centre by region. The boxes indicate median and interquartile range (IQR), the whiskers indicate 1.5
IQR, and the circles indicate individual outliers.
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133 (65.4%)) or non-academic centres (67 out of 119 (56.3%); p<0.001), as were centres in high-income
countries (250 out of 306 (81.7%)) compared with centres in other countries (100 out of 151 (66.2%);
p<0.001). ILD academic centres were more likely to have meetings at least once every 2 weeks (147 out of
196 (75.0%)) compared with non-ILD academic centres (51 out of 87 (58.6%)) and non-academic centres
(36 out of 67 (53.7%); p=0.001).
Most centres reported having pulmonology (n=349 (99.7%)) and radiology (n=320 (91.4%)) specialists in
attendance; a lower proportion reported having histopathology (n=232 (66.3%)) and rheumatology (n=130
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FIGURE 3 Key characteristics of formal meetings: a) frequency, b) length by cases discussed, c) disciplines in
attendance and d) interstitial lung disease cases discussed.
TABLE 3 Meeting characteristics by centre type, country income and region
Hold formal
meetings for
ILD cases
Hold meetings
every 2 weeks
or more
Hold meetings
solely
face-to-face
Hold meetings
of 31–60 min
duration
Have at least
four disciplines
in attendance
Centre type
ILD academic 196 (95.6) 147 (75.0) 156 (79.6) 97 (49.5) 129 (65.8)
Non-ILD
academic
87 (65.4) 51 (58.6) 78 (89.7) 49 (56.3) 44 (50.6)
Non-academic 67 (56.3) 36 (53.7) 46 (68.7) 32 (47.8) 29 (43.4)
Country income
High 250 (81.7) 167 (66.8) 209 (83.6) 131 (52.4) 152 (60.8)
Upper-middle 84 (68.9) 58 (69.0) 59 (70.2) 42 (50.0) 44 (52.4)
Lower-middle 15 (55.5) 8 (53.3) 11 (73.3) 5 (33.3) 5 (33.3)
Low 1 (50.0) 1 (100.0) 1 (100.0) 0 (0.0) 1 (100.0)
Region
Africa 8 (50.0) 5 (62.5) 8 (100.0) 6 (75.0) 3 (37.5)
Asia-Pacific 95 (79.2) 67 (70.5) 71 (74.7) 45 (47.4) 46 (48.4)
Europe 148 (85.5) 90 (60.8) 120 (81.1) 72 (48.6) 92 (62.2)
Middle East 10 (41.7) 5 (50.0) 9 (90.0) 5 (50.0) 5 (50.0)
North America 47 (74.6) 34 (78.7) 41 (87.2) 30 (63.8) 32 (68.1)
South and Latin
America
42 (68.9) 33 (78.6) 31 (73.8) 20 (47.6) 24 (57.1)
All centres 350 (76.6) 234 (66.9) 280 (80.0) 178 (50.9) 202 (57.7)
Data are presented as n (%). ILD: interstitial lung disease.
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(37.1%)) specialists in attendance (figure 4). ILD academic centres were more likely to have histopathology
specialists (n=145 (74.0%)) in attendance than non-ILD academic centres (n=49 (56.3%)) or non-academic
centres (n=38 (56.7%); p=0.003) (figure 4) and were also more likely to have rheumatology specialists
(n=83 (42.3%)) in attendance than other centres (n=30 (34.5%) and n=17 (25.4%), respectively; p=0.039).
Meeting scope
Most centres discussed diagnosis (n=346 (98.9%)), available diagnostic evidence (n=339 (96.9%)),
recommended diagnostic tests (n=334 (95.4%)) and available therapeutic treatment (n=332 (94.9%)).
Prognosis and supportive care were discussed by 86.0% (n=301) and 66.9% (n=234), respectively.
Access to antifibrotic agents
Antifibrotic agents (nintedanib or pirfenidone) were available to 372 of the 457 centres (81.4%), among
which 118 (31.7%) required the permission of an MDT for access. A greater proportion of ILD academic
centres had access to antifibrotics (180 out of 205 (87.8%)) than non-ILD academic centres (100 out of
133 (75.2%)) or non-academic centres (92 out of 119 (77.3%); p=0.006). However, ILD academic centres
were more likely to require MDT permission to access them (69 out of 180 (38.3%)) than either non-ILD
academic centres (20 out of 100 (20.0%)) or non-academic centres (29 out of 92 (31.5%); p=0.007). Of the
306 centres in high-income countries, 89.5% (n=274) had access to antifibrotics, compared with 64.8% (79
out of 122) in upper-middle-income countries and 70.4% (19 out of 27) in lower-middle-income countries
(p<0.001). Neither of the two centres in low-income countries had access to antifibrotics and only 25%
(four out of 12) of centres in Africa reported access, compared with almost all (62 out of 63 (98.4%))
centres in North America. In contrast to centres in North America (three out of 63 (4.8%)) and Africa
(none out of four (0.0%)), which rarely reported needing MDT permission to access antifibrotics, 45.6%
(67 out of 147) of centres in Europe required MDT permission.
BRIC countries
Reponses from BRIC countries (i.e. Brazil (n=10), Russia (n=25), India (n=19) and China (n=9))
accounted for 13.8% of all responses. Responses from BRIC countries were more often from academic ILD
centres (32 out of 963 (50.8%)) than non-BRIC countries (173 out of 394 (43.9%)), although India had
more non-academic centres (10 (52.6%)) than any other type. The BRIC countries discussed new cases in
an MDT meeting (n=53 (84.1%)) more often than non-BRIC countries (n=309 (78.4%)), although fewer
meetings were formal (median 50% compared with 80%)). 50% (n=5) of centres reported access to
antifibrotics in Brazil, 56% (n=14) of centres in Russia, and 100% of centres in India (n=19) and China
(n=9).
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Discussion
Knowledge of ILD diagnostic practices outside of well-characterised specialist centres is limited,
particularly those used within the BRIC nations that contribute almost half of the world’s population and
in lower-income settings. This inclusive, descriptive study is a first attempt to look beyond well-resourced
ILD centres and to understand diagnostic practice on a more global scale: across a range of countries,
income and resource settings. Although participating centres were ostensibly located in high-income (67%)
or middle-income (32.6%) countries, only 45% were self-described as academic ILD centres and there was
participation (at some level) from all global regions: Europe contributed 37.9% of centres, Asia-Pacific
26.3%, North America 13.8%, South and Latin America 13.3%, Middle East 5.3%, and Africa 3.5%.
Overall, almost 80% of the centres report discussing new ILD cases and referrals at MDT meetings
(ranging from 97% of academic ILD centres to 60% of non-academic centres). Although not designed to
be representative of the global ILD community, this broad respondent group suggests the MDT approach
to ILD diagnosis is widely adopted in routine care, across all participating countries, income and care
settings. While most centres appear to conduct face-to-face meetings, which could be assumed to facilitate
easier information exchange, the use of video conferencing and other remote communication aids may be
integral to accessing critical ILD expertise in remote and underresourced settings.
The structure of the MDT meetings described by participating centres was broadly similar, but a
“minimum MDT standard” remains hard to define. While some MDT meeting characteristics (e.g. length
and number of cases discussed) are likely to be driven by the number of cases seen by the centre, others
(e.g. range of specialities in attendance and diagnostic tests performed) may be influenced by available
resources or expertise. Consistent with this, speciality representation varied between centres. While
pulmonology was almost always represented (99.7% of centres), and radiology at most centres (91.4%),
histopathology specialist attendance was less frequent, with approximately a third of centres (including
26% of academic ILD centres) having no pathology attendee. It is possible this is driven by a low
proportion of cases requiring biopsies to establish diagnosis. However, given the crucial role of
histopathologists in lung biopsy interpretation and the inclusion of pathology attendance as a defining
factor of an MDT in two recent guidelines [6, 11], the reasons for this merit investigation. Further
research to determine the effect that such differences in MDT composition and practice have on the
diagnosis of ILD and subsequent outcomes is required, and is planned as a second phase of this research.
The lack of data from centres in low-income countries and uneven geographic distribution of responding
centres are key limitations of this study. While the multiple recruitment channels used ensured the
participant group was broad and inclusive, the self-selecting nature of respondents means it is unlikely to
be representative and may underestimate the true extent of ILD diagnostic heterogeneity.
Despite these limitations, the concept of the MDT appears to be embodied in real-world diagnostic
practice, with most centres, irrespective of global region, economic status, academic or ILD specialism,
conducting face-to-face formal meetings involving representatives of multiple specialities to discuss ILD
case diagnosis and management. This finding will inform the appropriate design of future diagnostic
agreements studies required to guide optimal diagnostic pathway recommendations. It may also be of
interest to those involved in the design and delivery of trial programmes for emerging ILD therapeutics
where recruitment efforts have traditionally been focused on a relatively small number of recognised ILD
centres whose pooled caseloads may struggle to meet growing enrolment demands.
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